Cost-Effectiveness of Pazopanib Versus Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma From the Health Insurance Perspective- A Markov Model
May 1, 2014, 00:00
10.1016/j.jval.2014.03.526
https://www.valueinhealthjournal.com/article/S1098-3015(14)00577-4/fulltext
Title :
Cost-Effectiveness of Pazopanib Versus Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma From the Health Insurance Perspective- A Markov Model
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00577-4&doi=10.1016/j.jval.2014.03.526
First page :
A90
Section Title :
Cancer
Open access? :
No
Section Order :
1578